Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Brendan P. O'grady is Chief Executive Officer at Nasus Pharma. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 14, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
1
Companies involved
1
Nasus PharmaNSRX
Oct 8, 2026210Kdisclosed Nov 14
DetailsOfficial recordBrendan P. O'grady has no open-market purchase on record since 2018. Sales in 4 of the 9 years since 2018.
Brendan P. O'grady reported 0 open-market purchases and 20 sales since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $1.44M9×9 trades |
| 2020 | — | $68K3×3 trades |
| 2019 | — | $55K4×4 trades |
| 2018 | — | $79K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Brendan P. O'grady has no open-market purchase on record since 2018. Sales in 4 of the 9 years since 2018.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2021.
Teva Pharmaceutical Industries (TEVA), from 2018 to 2021: 0 purchases and 20 sales.
Brendan P. O'grady reported 0 open-market purchases and 20 sales here, 2018 to 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.